Search clinical trials for: Zanubrutinib

Total 128 results

German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
BeiGene

Completed

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)

Waldenström's Macroglobulinemia

United States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
BeiGene

Completed

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma (MAGNOLIA)

Marginal Zone Lymphoma | MZL

China, Australia, Italy, France, New Zealand, Czechia, United Kingdom, United States, Korea, Republic of
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
The First Affiliated Hospital of Soochow University

Enrolling by invitation

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

China
BeiGene

Completed

Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

Healthy Volunteers

United States
BeiGene

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Lymphoma | Leukemia

China, Australia
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
Ruijin Hospital

Active, not recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

China
BeiGene

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM)

China
BeiGene

Completed

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

Australia, Korea, Republic of, United States
BeiGene

Completed

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

COVID-19 | COVID-19 Pulmonary Complications

United States
BeiGene

Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
BeiGene

Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Refractory Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma

China
BeiGene

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma

China
BeiGene

Completed

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

B-cell Lymphoma

China
BeiGene

Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma

China
BeiGene

No longer available

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Waldenström Macroglobulinemia

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
BeiGene

Completed

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Volunteers

United States
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
West-Ward Pharmaceutical

Completed

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

Asthma

United States
BeiGene

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Healthy Volunteers

United States
BeiGene

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

Healthy Volunteers

Australia
BeiGene

Completed

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Healthy Subjects

United States
BeiGene

Completed

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

Healthy Volunteers: Asian, Non-Asian

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece

3

Subscribe